These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27663942)

  • 41. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
    Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
    J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
    Fuentes J; Danckaerts M; Cardo E; Puvanendran K; Berquin P; De Bruyckere K; Montoya A; Quail D; Escobar R
    J Clin Psychopharmacol; 2013 Dec; 33(6):766-74. PubMed ID: 23963057
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can EEG Predict Response to Atomoxetine in attention deficit hyperactivity disorder at 1 Week?
    Singh G; Arun P; Das S; Kaur D
    J Atten Disord; 2021 Mar; 25(5):758-767. PubMed ID: 30762472
    [No Abstract]   [Full Text] [Related]  

  • 44. Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine.
    Thome J; Dittmann RW; Greenhill LL; Lipsius S; Tanaka Y; Bushe C; Escobar R; Heinloth AN; Upadhyaya H
    Atten Defic Hyperact Disord; 2017 Dec; 9(4):219-229. PubMed ID: 28477289
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
    Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
    Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
    Chang K; Nayar D; Howe M; Rana M
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
    Molife C; Haynes VS; Nyhuis A; Faries DE; Gelwicks S; Kelsey DK; Alatorre CI
    Curr Med Res Opin; 2018 Apr; 34(4):619-632. PubMed ID: 29298540
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
    Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
    Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder.
    Clemow DB; Nyhuis AW; Robinson RL
    CNS Neurosci Ther; 2016 Dec; 22(12):970-978. PubMed ID: 27476490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in serum miRNA-let-7 level in children with attention deficit hyperactivity disorder treated by repetitive transcranial magnetic stimulation or atomoxetine: An exploratory trial.
    Cao P; Wang L; Cheng Q; Sun X; Kang Q; Dai L; Zhou X; Song Z
    Psychiatry Res; 2019 Apr; 274():189-194. PubMed ID: 30807970
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment effects of combining social skill training and parent training in Taiwanese children with attention deficit hyperactivity disorder.
    Huang YH; Chung CY; Ou HY; Tzang RF; Huang KY; Liu HC; Sun FJ; Chen SC; Pan YJ; Liu SI
    J Formos Med Assoc; 2015 Mar; 114(3):260-7. PubMed ID: 25777975
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Driving performance in adults with ADHD: results from a randomized, waiting list controlled trial with atomoxetine.
    Sobanski E; Sabljic D; Alm B; Dittmann RW; Wehmeier PM; Skopp G; Strohbeck-Kühner P
    Eur Psychiatry; 2013 Aug; 28(6):379-85. PubMed ID: 23062837
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Atomoxetine on the Cognitive Functions in Treatment of Attention Deficit Hyperactivity Disorder in Children with Congenital Hypothyroidism: A Pilot Study.
    Yang R; Gao W; Li R; Zhao Z
    Int J Neuropsychopharmacol; 2015 Apr; 18(8):. PubMed ID: 25896257
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine.
    Ramos-Quiroga JA; Corominas-Roso M; Palomar G; Gomez-Barros N; Ribases M; Sanchez-Mora C; Bosch R; Nogueira M; Corrales M; Valero S; Casas M
    Psychopharmacology (Berl); 2014 Apr; 231(7):1389-95. PubMed ID: 24202115
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
    Holzer B; Lopes V; Lehman R
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
    Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
    J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.
    Arnold LE; Lindsay RL; Conners CK; Wigal SB; Levine AJ; Johnson DE; West SA; Sangal RB; Bohan TP; Zeldis JB
    J Child Adolesc Psychopharmacol; 2004; 14(4):542-54. PubMed ID: 15662146
    [TBL] [Abstract][Full Text] [Related]  

  • 60. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?
    Aman MG; Bukstein OG; Gadow KD; Arnold LE; Molina BS; McNamara NK; Rundberg-Rivera EV; Li X; Kipp H; Schneider J; Butter EM; Baker J; Sprafkin J; Rice RR; Bangalore SS; Farmer CA; Austin AB; Buchan-Page KA; Brown NV; Hurt EA; Grondhuis SN; Findling RL
    J Am Acad Child Adolesc Psychiatry; 2014 Jan; 53(1):47-60.e1. PubMed ID: 24342385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.